A Review on Five and Six-Membered Heterocyclic Compounds Targeting the Penicillin-Binding Protein 2 (PBP2A) of Methicillin-Resistant Staphylococcus aureus (MRSA)
Staphylococcus aureus is a common human pathogen. Methicillin-resistant Staphylococcus aureus (MRSA) infections pose significant and challenging therapeutic difficulties. MRSA often acquires the non-native gene PBP2a, which results in reduced susceptibility to β-lactam antibiotics, thus conferring resistance. PBP2a has a lower affinity for methicillin, allowing bacteria to maintain peptidoglycan biosynthesis, a core component of the bacterial cell wall. Consequently, even in the presence of methicillin or other antibiotics, bacteria can develop resistance. Due to genes responsible for resistance, S. aureus becomes MRSA. The fundamental premise of this resistance mechanism is well-understood. Given the therapeutic concerns posed by resistant microorganisms, there is a legitimate demand for novel antibiotics. This review primarily focuses on PBP2a scaffolds and the various screening approaches used to identify PBP2a inhibitors. The following classes of compounds and their biological activities are discussed: Penicillin, Cephalosporins, Pyrazole-Benzimidazole-based derivatives, Oxadiazole-containing derivatives, non-β-lactam allosteric inhibitors, 4-(3H)-Quinazolinones, Pyrrolylated chalcone, Bis-2-Oxoazetidinyl macrocycles (β-lactam antibiotics with 1,3-Bridges), Macrocycle-embedded β-lactams as novel inhibitors, Pyridine-Coupled Pyrimidinones, novel Naphthalimide corbelled aminothiazoximes, non-covalent inhibitors, Investigational-β-lactam antibiotics, Carbapenem, novel Benzoxazole derivatives, Pyrazolylpyridine analogues, and other miscellaneous classes of scaffolds for PBP2a. Additionally, we discuss the penicillin-binding protein, a crucial target in the MRSA cell wall. Various aspects of PBP2a, bacterial cell walls, peptidoglycans, different crystal structures of PBP2a, synthetic routes for PBP2a inhibitors, and future perspectives on MRSA inhibitors are also explored.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Molecules (Basel, Switzerland) - 28(2023), 20 vom: 10. Okt. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ambade, Shraddha S [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 30.10.2023 Date Revised 03.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/molecules28207008 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM363865101 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM363865101 | ||
003 | DE-627 | ||
005 | 20231226094239.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/molecules28207008 |2 doi | |
028 | 5 | 2 | |a pubmed24n1212.xml |
035 | |a (DE-627)NLM363865101 | ||
035 | |a (NLM)37894491 | ||
035 | |a (PII)7008 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ambade, Shraddha S |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Review on Five and Six-Membered Heterocyclic Compounds Targeting the Penicillin-Binding Protein 2 (PBP2A) of Methicillin-Resistant Staphylococcus aureus (MRSA) |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.10.2023 | ||
500 | |a Date Revised 03.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Staphylococcus aureus is a common human pathogen. Methicillin-resistant Staphylococcus aureus (MRSA) infections pose significant and challenging therapeutic difficulties. MRSA often acquires the non-native gene PBP2a, which results in reduced susceptibility to β-lactam antibiotics, thus conferring resistance. PBP2a has a lower affinity for methicillin, allowing bacteria to maintain peptidoglycan biosynthesis, a core component of the bacterial cell wall. Consequently, even in the presence of methicillin or other antibiotics, bacteria can develop resistance. Due to genes responsible for resistance, S. aureus becomes MRSA. The fundamental premise of this resistance mechanism is well-understood. Given the therapeutic concerns posed by resistant microorganisms, there is a legitimate demand for novel antibiotics. This review primarily focuses on PBP2a scaffolds and the various screening approaches used to identify PBP2a inhibitors. The following classes of compounds and their biological activities are discussed: Penicillin, Cephalosporins, Pyrazole-Benzimidazole-based derivatives, Oxadiazole-containing derivatives, non-β-lactam allosteric inhibitors, 4-(3H)-Quinazolinones, Pyrrolylated chalcone, Bis-2-Oxoazetidinyl macrocycles (β-lactam antibiotics with 1,3-Bridges), Macrocycle-embedded β-lactams as novel inhibitors, Pyridine-Coupled Pyrimidinones, novel Naphthalimide corbelled aminothiazoximes, non-covalent inhibitors, Investigational-β-lactam antibiotics, Carbapenem, novel Benzoxazole derivatives, Pyrazolylpyridine analogues, and other miscellaneous classes of scaffolds for PBP2a. Additionally, we discuss the penicillin-binding protein, a crucial target in the MRSA cell wall. Various aspects of PBP2a, bacterial cell walls, peptidoglycans, different crystal structures of PBP2a, synthetic routes for PBP2a inhibitors, and future perspectives on MRSA inhibitors are also explored | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a heterocycles | |
650 | 4 | |a high-throughput screenings | |
650 | 4 | |a mur enzymes | |
650 | 4 | |a penicillin-binding protein 2a (PBP2a) | |
650 | 4 | |a transpeptidation | |
650 | 7 | |a Penicillin-Binding Proteins |2 NLM | |
650 | 7 | |a Methicillin |2 NLM | |
650 | 7 | |a Q91FH1328A |2 NLM | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
650 | 7 | |a Monobactams |2 NLM | |
650 | 7 | |a Bacterial Proteins |2 NLM | |
700 | 1 | |a Gupta, Vivek Kumar |e verfasserin |4 aut | |
700 | 1 | |a Bhole, Ritesh P |e verfasserin |4 aut | |
700 | 1 | |a Khedekar, Pramod B |e verfasserin |4 aut | |
700 | 1 | |a Chikhale, Rupesh V |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 28(2023), 20 vom: 10. Okt. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2023 |g number:20 |g day:10 |g month:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules28207008 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 28 |j 2023 |e 20 |b 10 |c 10 |